Saturday, March 16
The Renaissance Newark Airport Hotel
Salon H
1000 Spring Street
Elizabeth, New Jersey

Saturday, March 23
Orlando World Center Marriott
Aruba/Bahamas Ballroom
8701 World Center Drive
Orlando, Florida

Judd W. Moul, MD
Director, Duke Prostate Center
James H. Semans, MD, Professor of Surgery
Duke University School of Medicine
Durham, North Carolina

Matthew T. Rosenberg, MD
Medical Director
Mid-Michigan Health Centers
Chief, Department of Family Medicine
Foote Health System
Jackson, Michigan

• Apply guidelines and evidence to the diagnosis and management of men with androgen deficiency syndromes
• Outline the safety, efficacy, and routes of administration of available testosterone replacement therapy (TRT) formulations
• Promote patient confidence in and adherence to TRT through improved communication
• Provide hands-on instruction of proper TRT application to patients with androgen deficiency syndromes
• Outline the benefits and limitations of available and newer agents for the medical management of early stage prostate cancer (PCa) and treatment side effects
• Take an active role in the multidisciplinary treatment plan to improve adherence and outcomes in PCa patients receiving ADT

NACCME designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for 3 contact hours (0.3 CEUs) of continuing pharmacy education (UAN 0276-0000-13-023-L01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Assistant Director, Accreditation Services, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535.  The Assistant Director, Accreditation Services will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Executive Director, Accreditation Services, NACCME, may be made for a second level of review.

This educational activity is a knowledge-based activity.

Independent clinical reviewer: Steven E. Canfield, MD, Chief, Division of Urology, University of Texas Medical School at Houston, Houston, Texas

Nurse planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.  

The faculty has reported the following: 

Dr. Gomella: Consultant—AVEO, Astellas, Bayer, COBI, Dendreon, Ferring;  Clinical trial—Amgen, COBI, Endo

Dr. Miner: Consultant—Merck; Investigator—Auxilium Pharmaceuticals, Inc.

Dr. Moul: Advisory board consultant—Medivation-Astellas, Myriad; Promotional speakers bureau—Amgen, Dendreon, Ferring, Janssen Pharmaceuticals, Inc., Sanofi

Dr. Rosenberg: Consultant—Astellas, Ferring, Horizon, Lilly, Pfizer; Promotional speakers bureau—Astellas, Forest, Horizon, Orth-McNeil, Pfizer

Ms. Seaman: Consultant—Healthpoint Biotherapeutics; Scientific advisor—Molnlycke Health Care

Dr. Canfield disclosed no relevant financial relationships with any commercial interests.

Mr. Chavez, Mr. Robbin, Mr. Savage, and Ms. Steuerman have disclosed no relevant financial relationships with any commercial interests.

Mr. Kearney: Stock Shareholder—Savient Pharmaceuticals, Inc.
Mr. Lombardi: Stock Shareholder — Vertex Pharmaceuticals, Inc.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed that no off-label/unapproved uses of drugs and/or devises will be discussed in the presentations.

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2013 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.